Thiazides and Calcium Stones: Overrated or Underused?

  • John J. Knoedler
  • Amy E. KrambeckEmail author


The lifetime incidence of urolithiasis is approximately 10–15 % in the USA, with calcium-containing stones the most common offender. Among recurrent stone formers, thiazide-type diuretics have traditionally represented first-line therapy for prevention of recurrent calcium stones. However, with improved understanding of the benefits of lifestyle modification and alternative therapies for stone prevention, the utility of thiazides as first-line agents has recently come into question. This chapter will explore the rational for thiazide usage in the prevention of recurrent calcium stone disease, evaluate the evidence in favor of and against thiazides as first-line therapy, and finally examine the cost-effective use of thiazides and their comparative effectiveness to alternative forms of treatment.


Nephrolithiasis Stones kidney Thiazide diuretic Hypercalciuria 


  1. 1.
    Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-walsh urology. 10th ed. Philadelphia: Saunders Elsevier; 2012.Google Scholar
  2. 2.
    Pearle MS, Calhoun EA, Curhan GC. Urologic diseases in America project: urolithiasis. J Urol. 2005;173(3):848–57.PubMedCrossRefGoogle Scholar
  3. 3.
    Brocks P, Dahl C, Wolf H, Transbøl I. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet. 1981;2(8238):124–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol. 1982;128(5):903–7.PubMedGoogle Scholar
  5. 5.
    Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand. 1984;215(4):383–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson D, Strauss A, Manuel M. Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res. 1984;12:39–40.Google Scholar
  7. 7.
    Robertson WG, Peacock M, Selby PL, Williams RE, Clark P, Chisholm GD, et al. A multicentre trial to evaluate three treatments for recurrent idiopathic calcium stone disease—a preliminary report. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, editors. Urolithiasis and related clinical research. New York: Plenum Press; 1985.p. 545–8.CrossRefGoogle Scholar
  8. 8.
    Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol. 1986;18(3):265–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139(4):679–84.PubMedGoogle Scholar
  10. 10.
    Ohkawa M, Tokunaga S, Nakashima T, Orito M, Hisazumi H. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol. 1992;69(6):571–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol. 1993;22(6):78–86.Google Scholar
  12. 12.
    Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, Arrabal-Polo MA, Pichardo-Pichardo S, Zuluaga-Gómez A. Papel de las tiazidas en la profilaxis de la litiasis cálcica recidivante. Actas Urológicas Españolas. 2006;30:305–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Park S, Pearle MS. Pathophysiology and management of calcium stones. Urol Clin North Am. 2007;34(3):323–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Pak CY. Pharmacotherapy of kidney stones. Expert Opin Pharmacother. 2008;9(9):1509–18.PubMedCrossRefGoogle Scholar
  15. 15.
    Lamberg BA, Kuhlback B. Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine. Scand J Clin Lab Invest. 1959;11:351–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Huen SC, Goldfarb DS. Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol. 2007;177(4):1238–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Escribano J, Balaguer A, Pagone F, Feliu A, Roqué I, Figuls M. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004754.Google Scholar
  18. 18.
    Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893–1903.PubMedCrossRefGoogle Scholar
  19. 19.
    Pearle MS, Roehrborn CG, Pak CY. Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol. 1999;13(9):679–85.PubMedCrossRefGoogle Scholar
  20. 20.
    Vigen R, Weideman R, Reilly R. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol. 2011;43(3):813–9.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Asplin JR, Bauer KA, Kinder J, Müller G, Coe BJ, Parks JH, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int. 2003;63(2):662–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Asplin JR, Donahue S, Kinder J, Coe FL. Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int. 2006;70(8):1463–7.PubMedCrossRefGoogle Scholar
  23. 23.
    de Cogain M, Krambeck A. Pathogenesis of stone disease. AUA Update Series. 2011;30(Lesson 3):25–31.Google Scholar
  24. 24.
    Pak CY, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med. 1986;146(5):863–7.PubMedCrossRefGoogle Scholar
  25. 25.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981–97.CrossRefGoogle Scholar
  26. 26.
    Eisner BH, Goldfarb DS, Pareek G. Pharmacologic treatment of kidney stone disease. Urol Clin North Am. 2013;40(1):21–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742–8.CrossRefGoogle Scholar
  28. 28.
    Lotan Y, Pearle MS. Economics of stone management. Urol Clin North Am. 2007;34(3):443–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Lotan Y, Cadeddu JA, Roerhborn CG, Pak CY, Pearle MS. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol. 2004;172(6 Pt 1):2275–81.Google Scholar
  30. 30.
    Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. European Urology. 2009;56(1):72–80.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Inter Med. 2013;158(7):535–43.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of UrologyMayo ClinicRochesterUSA

Personalised recommendations